---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107984"
form_type: "8-K"
ticker: "CVSI"
cik: "0001510964"
company_name: "CV Sciences, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:55:06.578131+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CV Sciences Q2 revenue $3.6M (-8% YoY); first positive adjusted EBITDA in six years

## Summary
- Revenue $3.6M, down 8% from $4.0M in Q2 2024; units sold down 7%, avg price down 2.8%.
- Gross margin 50.9%, highest since Q3 2019, up from 47.0% in Q2 2024.
- Adjusted EBITDA positive $0.1M, first since Q2 2019, vs -$6k in Q2 2024.
- Cash balance $0.9M at quarter end, up from $0.5M at end of 2024.
- CEO cites state regulatory pressure for sales decline; pushing M&A and new products.

## SEC filing metadata
- accession: 0000950170-25-107984
- form_type: 8-K
- ticker: CVSI
- cik: 0001510964
- company_name: CV Sciences, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1510964/000095017025107984/0000950170-25-107984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1510964/000095017025107984/cvsi-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107984
- JSON: https://secwatch.observer/filing/0000950170-25-107984.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107984.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.